The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to
4.8 (368) · $ 6.50 · In stock
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials - ScienceDirect
Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion, BMC Cancer
Monika DAVARE, Professor (Associate), PhD
Targeted therapy for rare lung cancers: Status, challenges, and prospects - ScienceDirect
CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles, Journal of Translational Medicine
The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to all
The Role of Introns for the Development of Inflammation-Mediated Cancer Cell
Inna Khodos's research works Memorial Sloan Kettering Cancer
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. - Abstract - Europe PMC
.jpg)
)